PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 3

Complete if Known	
Application Number	Not yet assigned
Filing Date	Herewith
First Named Inventor	Steven D. Schwartz
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	96700/855

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] *(if known)*	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	US- 6,185,548 B1	02-06-2001	Schwartz et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] *(if known)*	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 3

Complete if Known	
Application Number	Not yet assigned
Filing Date	Herewith
First Named Inventor	Steven D. Schwartz
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	96700/855

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	2	BAGDASSARIAN et al., Molecular Electrostatic Potential Analysis for Enzymatic Substrates, Competitive Inhibitors, and Transition-State Inhibitors. J. Am. Chem. Soc., 118:8825-36, 1996.	
	3	BETTS et al., Cytidine Deaminase. The 2-3 Angstrom Crystal Structure of an Enzyme: Transition-state Analog Complex. J. Mol. Biol., 235:635-56, 1994.	
	4	BOHM, New Approaches in Molecular Structure Prediction. Biophysical Chemistry, 59:1-32, 1996.	
	5	BRUSIC et al., Prediction of MHC Class II-Binding Peptides Using an Evolutionary Algorithm and Artificial Neural Network. Bioinformatics, 14:121-30, 1998.	
	6	EHRLICH and SCHRAMM, Electrostatic Potential Surface Analysis of the Transition State for AMP Nucleosidase and for Formycin 5'-Phosphate, a Transition-State Inhibitor. Biochem., 33:8890-96, 1994.	
	7	FRICK et al., Binding of Pyrimidin-2-one Ribonucleoside by Cytidine Deaminase as the Transition-State Analogue 3,4-Dihydrouridine and the Contribution of the 4-Hydroxyl Group to Its Binding Affinity. Biochemistry, 28:9423-30, 1989.	
	8	GASTEIGER et al., Representation of Molecular Electrostatic Potentials by Topological Feature Maps. J. Am. Chem. Soc., 116:4608-20, 1994.	
	9	HORENSTEIN and SCHRAMM, Electronic Nature of the Transition State for Nucleoside Hydrolase. A Blueprint for Inhibitor Design. Biochemistry, 32:7089-97, 1993.	
	10	KLINE and SCHRAMM, Electrostatic Potential Surfaces of the Transition State for AMP Deaminase and for (R)-Coformycin, a Transition State Inhibitor. J. Biol Chem., 269:22385-90, 1994.	
	11	SO and RICHARDS, Application of Neural Networks: Quantitative Structure-Activity Relationships of the Derivatives of 2,4-Diamino-5-(substituted-benzyl) pyrimidines as DHFR Inhibitors. J. Med. Chem., 35:3201-7, 1992.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 3 of 3

Complete if Known	
Applicati n Number	Not yet assigned
Filing Dat	Herewith
First Named Inventor	Steven D. Schwartz
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	96700/855

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	12	WAGENER et al., Autocorrelation of Molecular Surface Properties for Modeling Corticosteriod Binding Globulin and Cytosolic Ah Receptor Activity by Neural Networks. J. Am. Chem. Soc., 117:7769-75, 1995.	
	13	WEINSTEIN et al., Predictive Statistics and Artificial Intelligence in the U.S. National Cancer Institute's Drug Discovery Program for Cancer and AIDS. Stem Cells, 12:13-22, 1994.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.